HIV vaccine research receives $7.8 million in grants from NIH

The National Institute of Health's National institute of Allergy and Infectious Diseases has awarded 14 grants to fund basic research to identify new approaches to designing a safe and effective HIV vaccine.

The grants are part of the Innovation for HIV Vaccine Discovery initiative that is expected to receive up to $34.8 million over the next for years, according to a release from the National Institute of Health.

"Recent discoveries about the basic biology of HIV and how the virus adapts to its host have provided useful information and new opportunities to guide vaccine development," NIAID Director Anthony S. Fauci said. "These grants are designed to build on that information and stimulate discovery of new ways to design a robust vaccine that prevents acquisition and establishment of latent infection."

The 14 IHVD grant recipient organizations include Altravax, Inc., the Catholic University of America, Dartmouth College, Duke University, Harvard Medical School, Massachusetts General Hospital, the NYU Langone Medical Center, the University of California - Irvine), the University of Maryland, the University of Medicine and Dentistry of New Jersey, the University of Minnesota, the University of North Carolina, the University of Rochester and the University of Texas - El Paso.

NIAID supports research studying the cause of infectious and immune-mediated diseases so as to better prevent, diagnose and treat such illnesses. The National Institute of Health includes 27 Institutes and Centers and is part of the U.S. Department of Health and Human Services.